3D render of Listeria monocytogenes bacteria

Publication of Data on the Novel Antibiotic CRS0540

Aug 15, 2022 | Press Releases

Announcement Regarding CRS0540:

Crestone, Inc. and Praedicare Inc. Announce the Publication of Data on the Novel Antibiotic CRS0540 in the Hollow Fiber System Model of the Orphan Disease Disseminated Listeriosis

August 15, 2022—End-to-end drug development company Praedicare has found promise in a potential treatment for listeriosis using Crestone’s antibacterial drug candidate CRS0540. Read more about these exciting findings in the press release below, published on Cision PR Newswire’s website:

https://www.prnewswire.com/news-releases/crestone-inc-and-praedicare-inc-announce-the-publication-of-data-on-the-novel-antibiotic-crs0540-in-the-hollow-fiber-system-model-of-the-orphan-disease-disseminated-listeriosis-301606053.html

Become a Part of Our Projects

Interested in helping further our research into novel antibacterial agents? We’d be thrilled to have your help, either as an investor, a team member, or a participant in our ongoing clinical studies.

Inquiries

Have a question or comment? Follow the link below to contact us about general inquiries.

Contact Us

Careers

Find work in a team-oriented environment at one of the leading Colorado pharma companies.

Join Crestone

Investors

If you're interested in becoming an investor to help fund our research and development, contact us today.

Contact Us